Results 181 to 190 of about 24,684 (197)

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2006
Jeffrey S Heier
exaly  

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2011
Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald   +2 more
exaly  

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

New England Journal of Medicine, 2015
Lee M Jampol, Lloyd Paul Aiello, Jennifer K Sun   +2 more
exaly  

Ranibizumab

Reactions Weekly, 2014
  +4 more sources

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology, 2019
Peter A Campochiaro, Carl Regillo, Katie F Maass   +2 more
exaly  

Ranibizumab for Diabetic Macular Edema

Ophthalmology, 2012
Sunil Patel
exaly  

Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration

Ophthalmology, 2014
Allen C Ho, Thomas A Ciulla
exaly  

Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity

Ophthalmology, 2017
Ping Fei, Yu Xu, Jie Peng
exaly  

Ranibizumab

Drugs of the Future, 2003
null Sorbera, L.A., null Leeson, P.A., null Bayes, M.   +2 more
openaire   +1 more source

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen

Ophthalmology, 2019
Alex P Hunyor, Andrew Chang, Robyn H. Guymer   +2 more
exaly